2015

Coping with Cancer Survey

Northwoods NETs has received a request from East Tennessee State University to share a survey on coping with cancer to our community. Please see the letter and link for this survey below: Hello, my name is Jameson K. Hirsch, Ph.D., and I am a Clinical Psychologist at East Tennessee State University. I have received approval from the Institutional Review Board at my University to conduct a survey focused on well-being

Worldwide NET Cancer Day

NORTHWOODS NETS http://www.northwoodsnets.org info@northwoodsnets.org Contact: Dawn Marie Peterson dawnmarie@northwoodsnets.org 612.314.9997   GOVERNOR MARK DAYTON PROCLAIMS NOVEMBER 10, 2015 AS NET CANCER DAY Just a year after a Burnsville woman lost her mother to pancreatic neuroendocrine cancer—the cancer that took the life of entrepreneur Steve Jobs—her youngest son was diagnosed with the same type of tumors in his pancreas. The following year, another teenage son was also diagnosed with this disease.

NET Cancer Day Awareness PSA

Trey Anastasio, singer/songwriter and brother of a neuroendocrine cancer patient who succumbed to the disease six years ago, made this video to help raise awareness for rare Neuroendocrine Cancers. NET Cancer Day is November 10th. Please share and help spread information about this incurable cancer.    

Net Cancer Day 2015

We are pleased to announce that Governor Dayton has proclaimed November 10, 2015 as NET Cancer Day in the state of Minnesota. This is the fourth year that he has offered his support in raising awareness for rare neuroendocrine cancers. The proclamation reads as follows: State of Minnesota PROCLAMATION Whereas:  Neuroendocrine tumors (NETS) often develop into cancer and, if left untreated, can result in serious illness and death; and Whereas: 

PRRT offers longer progression free survival

New results from the NETTER-1 study that compared Sandostatin LAR 60mg versus treatment with the novel peptide receptor radionuclide therapy (PRRT) Lutathera have been made available. These findings, released at the 2015 European Cancer Congress, show that for patients living with unresectable mid-gut neuroendocrine cancers that PRRT provided a longer progression free survival than with just long-acting somastatin analogues alone. Read more about the findings of this study.